Startups
Categories: BusinessFinTechInformationWebsite
The Investor Relations website contains information about Eli Lilly and Company's business for stockholders, potential investors, and financial analysts.
Mentions
325
Overview
Location
United States, California, San Diego
Mentions in press and media 325
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Oct 29, 2026 | Eli Lilly hikes sales outlook, as CEO says there’s room for ‘dramatic’ obesity market expansion | Eli Lilly reported third-quarter earnings and revenue that blew past estimates and hiked its full-year sales outlook. Demand for its obesity drug Zepbound and diabetes treatment Mounjaro surged again and topped estimates for the quarter. De... |
| Aug 19, 2026 | Lilly Stock Rises on Alzheimer Deal: Retatrutide Moat Still Not Fully Priced | By Shannon Harwood Published: Aug 19 2026, 11:59 AM EDT Share on Facebook Share on Twitter Share on LinkedIn Share on Reddit Share on Flipboard |
| Aug 4, 2026 | Eli Lilly Formalizes Retatrutide Access With Criteria Most Patients Cannot Meet | By Adrian Parham Published: Aug 04 2026, 5:45 AM EDT Share on Facebook Share on Twitter Share on LinkedIn Share on Reddit Share on Flipboard |
| Jul 29, 2026 | Voice AI Flags Cognitive Decline From Ordinary Speech, Catching What Clinicians Miss | By Jackie Manning Published: Jul 29 2026, 6:22 AM EDT Share on Facebook Share on Twitter Share on LinkedIn Share on Reddit Share on Flipboard |
| Jul 24, 2026 | Pharma Giants Clash Over GLP-1 Ad Truths | Novo Nordisk launched a major lawsuit against Eli Lilly. It alleges pervasive misleading advertising for Lilly’s prominent GLP-1 drugs, Zepbound and Mounjaro. Novo claims Lilly’s nationwide campaigns leverage outdated clinical trials. They ... |
| Jul 23, 2026 | AI Diet Tools Have a Multicultural Blind Spot: NUTRITION 2026 Convenes Saturday in National Harbor | By Devin Culbertson Published: Jul 23 2026, 11:10 AM EDT Share on Facebook Share on Twitter Share on LinkedIn Share on Reddit Share on Flipboard |
| Jul 21, 2026 | Novo Nordisk sues Eli Lilly, alleging misleading GLP-1 advertising | Novo Nordisk filed a lawsuit against Eli Lilly, alleging that its advertising campaigns for its blockbuster obesity and diabetes drugs are designed to mislead consumers about their superior efficacy relative to the Danish drugmaker’s rival ... |
| Jul 15, 2026 | Alzheimer’s Blood Test Matches Brain Scan in Symptom-Free Adults, JAMA Study Shows | By Luke McKenzie Published: Jul 15 2026, 11:30 AM EDT Share on Facebook Share on Twitter Share on LinkedIn Share on Reddit Share on Flipboard |
| Jun 23, 2026 | Eli Lilly Chose One 79-Year-Old for Retatrutide While Millions Rely on Gray Market | By Chase Fiorini Published: Jun 23 2026, 1:24 PM EDT Share on Facebook Share on Twitter Share on LinkedIn Share on Reddit Share on Flipboard |
| May 23, 2026 | Новый экспериментальный препарат для похудения обеспечил резкое снижение веса | По данным компании Eli Lilly, участники исследования, которым вводили препарат ретатрутид, через 80 недель в среднем сбросили 28 процентов своей массы тела. Экспериментальный препарат помог участникам крупного клинического испытания похудет... |
| May 19, 2026 | Trump bought stock in drugmaker as his government boosted its obesity drugs | Getting your Trinity Audio player ready... By Darius Tahir, KFF Health News President Donald Trump earlier this year bought as much as $680,000 in stock of Eli Lilly, the maker of blockbuster obesity drugs, as the agencies he oversees under... |
| Mar 31, 2026 | Lilly to spend up to $7.8 billion to acquire Centessa, a maker of experimental sleep disorder drugs | Eli Lilly will pay up to $7.8 billion to acquire Centessa Pharmaceuticals. Centessa is developing orexin agonists to treat narcolepsy and excessive drowsiness. The deal is the latest from Lilly, which is using its GLP-1 windfall to place mo... |
| Mar 29, 2026 | Eli Lilly reaches $2.75 billion deal with Insilico to bring AI-developed drugs to the global market | Hong Kong-listed Insilico Medicine has reached a deal with U.S. pharma giant Eli Lilly for AI-discovered drugs. The two companies have worked together since 2023. Insilico’s CEO, Alex Zhavoronkov, said Eli Lilly has a competitive edge in ce... |
| Mar 23, 2026 | U.S. executives, from Apple to Eli Lilly, revamp their push into the world’s second-largest economy at the China Development Forum | Household names were among the more than 30 U.S. corporate executives who joined the China Development Forum in Beijing over the weekend. Fresh off a recovery in Apple iPhone sales in China, CEO Tim Cook took the stage on Sunday after Chine... |
| Mar 19, 2026 | Eli Lilly’s next-generation obesity drug retatrutide clears first late-stage diabetes trial | Eli Lilly said its next-generation obesity drug retatutride cleared its first late-stage trial on Type 2 diabetes patients, helping them manage their blood sugar levels and lose weight. The drug lowered hemoglobin A1C by an average of 1.7% ... |
| Feb 28, 2026 | Novo Nordisk Faces Setback as Key Weight Loss Drug Falls Short | Novo Nordisk experienced a significant blow. Its experimental weight-loss medication, CagriSema, failed to meet expectations in a crucial clinical trial. The drug did not demonstrate non-inferiority against Eli Lilly's rival product, t... |
| Feb 23, 2026 | Novo Nordisk sinks 15% after weight loss drug fails to match Eli Lilly’s in trial | Novo’s drug, CagriSema, didn’t achieve its key goal of demonstrating non-inferiority on weight loss when compared to Eli Lilly’s rival drug tirzepatide. The stock plummeted on Monday, hitting its lowest level since June 2021. The Danish dru... |
| Feb 9, 2026 | 2 stocks to hit $1 trillion market cap in Q1 2026 | As equity markets move deeper into 2026, more stocks are showing potential to join the $1 trillion club despite recent volatility. Notably, several candidates are supported by strong fundamentals, including earnings momentum, sector-specifi... |
| Jan 15, 2026 | Converge Bio Ignites AI Drug Discovery with $25M Investment | Converge Bio secured $25 million in Series A funding, bringing total capital to $30 million. This propels its generative AI platform, transforming drug discovery. The company deploys integrated AI systems, not just models, directly into R&a... |
| Jan 13, 2026 | Converge Bio raises $25M to accelerate drug discovery using generative AI solutions Send us a News Tip EXTRACT THE SIGNAL FROM THE NOISE Cookies | Accelerated drug discovery and development platform Converge Bio Inc. today announced it has raised $25 million in early-stage funding to develop better drugs for pharmaceutical companies and open up opportunities in the industry using arti... |
| 2026 | Novo Nordisk enters 2026 on the defense as it faces a ‘must-win’ battle in the U.S. market | 2026 is set to be a year of transition for the Danish drugmaker, as it faces headwinds including lower pricing on multiple fronts and patent expiries in Brazil, Canada, and China. It follows a difficult year for Novo, marked by volatility a... |
| Dec 25, 2025 | Oral GLP-1 Revolution: Novo Nordisk Secures First FDA Approval for Obesity Pill | The FDA approved Novo Nordisk's pivotal GLP-1 pill for obesity. This oral treatment, launching early 2026 at $149/month, revolutionizes weight loss access and patient choice. It secures Novo Nordisk a critical first-mover advantage ove... |
| Dec 23, 2025 | Novo Nordisk stock surges on hopes Wegovy pill approval will deliver ‘redemption’ for investors | The FDA on Monday approved the first-ever GLP-1 pill from Novo Nordisk. The approval gives the Danish pharma giant a head start against U.S. rival Eli Lilly. “Novo actually might have an edge, and it will entirely depend on how they execute... |
| Dec 18, 2025 | Eli Lilly says obesity pill helps maintain weight loss after patients switch from Wegovy, Zepbound | Eli Lilly said its closely watched obesity pill helped patients maintain the majority of their weight loss after they switched directly from taking Wegovy and Zepbound injections in a late-stage trial. The company also said it has filed for... |
| Nov 21, 2025 | Eli Lilly hits $1 trillion market value, a first in health care, as Novo Nordisk tumbles | Drugmaker Eli Lilly reached a $1 trillion market capitalization, the first health-care company in the world to join the exclusive club dominated by tech firms. The pharmaceutical giant’s stock has been riding the skyrocketing demand for its... |
| Nov 17, 2025 | Novo Nordisk cuts direct-to-consumer prices for Wegovy, Ozempic to $349 a month | Novo Nordisk said it is lowering the direct-to-consumer prices of its blockbuster weight loss drug Wegovy and diabetes counterpart Ozempic to $349 per month from $499 per month for existing cash-paying patients. The company also launched a ... |
| Aug 14, 2025 | Eli Lilly hikes price of diabetes drug Mounjaro in UK as Trump pressures pharma to align drug costs | Eli Lilly said it is raising the list price of its blockbuster diabetes drug Mounjaro in the U.K. starting in September. It comes as President Donald Trump pressures drugmakers to lower U.S. drug prices and hike them abroad under a controve... |
| Apr 15, 2025 | ChatGPT reveals two stocks to buy with $1,400 IRS payment | Some of us might be due for a windfall in the form of a $1,400 IRS payment. Today is Tax Day, and on top of that, the last day that you can apply to claim a recovery rebate credit for 2021. Confused? During the pandemic, the government sent... |
| Mar 25, 2025 | The Weight of Expectations: A Look at the Obesity Drug Market's Rollercoaster Ride | The obesity drug market is a battleground, where hopes soar and plummet with each trial result. Recent developments from Novo Nordisk and Eli Lilly illustrate this volatile landscape. Both companies are vying for dominance in a sector proje... |
| Mar 24, 2025 | 'Money Is Pouring In': President Donald Trump Announces Hyundai, Other Companies Investing Billions in U.S. At the White House on Monday, Trump announced that Hyundai is investing $20 billion in the U.S. | South Korean-based Hyundai announced a $20 billion investment in the U.S., CNBC reported. President Donald Trump made the announcement alongside Hyundai Chairman Euisun Chung and Louisiana Gov. Jeff Landry at the White House on Monday. The ... |
| Mar 24, 2025 | Eli Lilly will soon release key data on its weight loss pill. Here’s why it could be a game-changer | Eli Lilly plans to release initial results from several late-stage clinical trials on its experimental once-daily obesity pill, orforglipron, this year. The trial results are among the pharmaceutical industry’s most critical of the year, as... |
| Jan 15, 2025 | Here’s why Eli Lilly stock is crashing | Eli Lilly (NYSE: LLY) saw its stock decline sharply by 6.5% on January 14, following the release of its fourth-quarter 2024 revenue guidance, which fell short of Wall Street expectations. The pharmaceutical giant now projects $13.5 billion ... |
| Dec 5, 2024 | Gov. Evers, Eli Lilly and Company Celebrate $3 Billion Expansion of Manufacturing Facility in Wisconsin | Architectural rendering of expansion project for Eli Lilly According to the company, the investment will benefit millions of patients worldwide create 2,000 construction jobs and add 750 highly skilled jobs to Southeastern Wisconsin KENOSHA... |
| Oct 31, 2024 | Wall Street sets Eli Lilly stock price for the next 12 months | The ongoing earnings season has been filled with surprises in both directions. Some notable examples are Advanced Micro Devices (NASDAQ: AMD), which severely disappointed investors, and Garmin (NYSE: GRMN), which proved a surprise blockbust... |
| Aug 8, 2024 | Lilly Reports Q2 2024 Financial Results, Raises Full-Year Revenue Guidance by $3 Billion | Revenue in Q2 2024 increased 36%, driven by Mounjaro, Zepbound and Verzenio. When excluding $579.0 million of revenue from the sale of rights for Baqsimi in Q2 2023, revenue in Q2 2024 increased 46%. Excluding the sale of rights for Baqsimi... |
| Jul 26, 2024 | Pharmaceutical stocks to watch for end of 2024 | Pharma stocks can be strong investments regardless of economic conditions, as this stability arises because the demand for medications and healthcare services remains steady, even when prices rise. Pharmaceutical stocks tend to be more resi... |
| Jul 20, 2024 | Why millions are trying alternatives to Big Pharma's weight loss drugs | Pharmacist Mark Mikhael has lost 50 pounds over the past 12 months. He no longer has diabetes and finds himself "at my ideal body weight," with his cholesterol below 200 for the first time in 20 years. "I feel fantastic,"... |
| Jul 10, 2024 | Health | Mounjaro bests Ozempic for weight loss in first head-to-head comparison of real-world use | The findings were published Monday in JAMA Internal Medicine. Dr. Matthew Freeby, an endocrinologist and director of the Gonda Diabetes Center at UCLA’s Geffen School of Medicine, said the study results are in line with what he has observed... |
| Jul 8, 2024 | Lilly to Acquire Morphic to Improve Outcomes for Patients with Inflammatory Bowel Disease | Acquisition to expand Lilly's immunology pipeline with oral integrin therapies INDIANAPOLIS and WALTHAM, Mass., July 8, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Morphic Holding, Inc. (NASDAQ: MORF) today announced a d... |
| Jul 3, 2024 | FDA approves new Alzheimer's treatment, donanemab from Eli Lilly | The Food and Drug Administration approved a new Alzheimer's treatment called donanemab on Tuesday, clearing the way for the third addition to a new class of drugs aimed at slowing the brain's decline in patients facing the early s... |
| Jul 3, 2024 | Analysts revise Eli Lilly stock price targets | Eli Lilly (NYSE: LLY) recently made headlines with positive drug trial results for its GLP-1 weight-loss drug and its approval in China. But there might be some potential trouble ahead, as U.S. President Joe Biden called on pharmaceutical c... |
| May 16, 2024 | Средства для похудения — следующее чудо-лекарство? | Содержание Что такое агонисты GLP-1? Болезнь Паркинсона Наркотическая и алкогольная зависимость Ночное апноэ Бесплодие Психические заболевания Болезнь Альцгеймера Что такое агонисты GLP-1? Агонистами называются соединения, которые способны ... |
| Apr 30, 2024 | Lilly Reports First-Quarter 2024 Financial Results and Raises Full-Year Revenue Guidance by $2 Billion, Highlights Pipeline Momentum | Revenue in Q1 2024 increased 26%, driven by Mounjaro, Zepbound, Verzenio and Jardiance. Pipeline progress included positive results from two Phase 3 trials of tirzepatide for obstructive sleep apnea; submission of mirikizumab for Crohn'... |
| Apr 18, 2024 | Eli Lilly's weight-loss drug Zepbound could treat sleep apnea | Eli Lilly said Wednesday that its weight-loss drug Zepbound improved symptoms in two late-stage trials of patients with obstructive sleep apnea. Why it matters: If treating sleep apnea ultimately earns an FDA green light, it could expand in... |
| Apr 17, 2024 | Another perk of weight-loss drugs? Eli Lilly's Zepbound may alleviate sleep apnea, too | Health Another perk of weight-loss drugs? Eli Lilly's Zepbound may alleviate sleep apnea, too Hilary Brueck 2024-04-17T10:15:02Z Share icon An curved arrow pointing right. Share Facebook Icon The letter F. Facebook Email icon An envelo... |
| Mar 8, 2024 | FDA delays action on Lilly's Alzheimer's drug | The Food and Drug Administration is asking outside advisors to review the safety and efficacy of an experimental Alzheimer's drug from Eli Lilly that was expected to be approved in the first quarter of this year. Why it matters: Donane... |
| Mar 8, 2024 | Eli Lilly's new ad says weight-loss drugs shouldn't be used out of "vanity" | Eli Lilly has a message for people who are taking prescription medications developed for patients with Type 2 diabetes and obesity: Don't take the drugs just because you want to look good. The message, delivered in a new Hollywood-them... |
| Feb 20, 2024 | Health | Inside the plan to diagnose Alzheimer’s in people with no memory problems — and who stands to benefit | Melody Petersen | Los Angeles Times (TNS) In a darkened Amsterdam conference hall this summer, a panel of industry and academic scientists took the stage to announce a plan to radically expand the definition of Alzheimer’s disease to includ... |
| Feb 15, 2024 | Weight-Loss Drugs: Cost and Cost-Effectiveness | Drugs like Wegovy and Zepbound are effective in helping people lose weight, but the high price tag keeps them out of reach for many. Our series on weight-loss drugs continues with a look at the drugs’ cost and whether they are cost-effectiv... |
| Feb 6, 2024 | Vertex still knows how to do what it does best | Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Hello, everyone. Damian here with a close read of the latest blockbuster deal, a look at Novartis’ multibillion-doll... |
| Jan 16, 2024 | Georgetown Study Sparks Hope for Reversing Alzheimer's from Head Trauma | Inno Flores, Tech Times 16 January 2024, 10:01 pm |
| Jan 5, 2024 | Eli Lilly to sell weight-loss drugs directly to patients | Eli Lilly is poised to sell medicine directly to consumers — with an emphasis on newly popular weight-loss drugs — in a move toward cutting out the controversial middle players in drug distribution. Why it matters: Pharmaceutical companies ... |
| Jan 4, 2024 | Why CG Oncology will be the first test of 2024’s IPO waters | Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning, everyone. Damian here with an in-depth preview of a certain annual biotech conference, a look at the c... |
| Dec 18, 2023 | The legal pathway for experimental, ultra-rare disease treatments is rocky and expensive | Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Today, we see a small biotech on the verge of ending a rare-disease program thanks to FDA difficulties — and how tha... |
| Nov 2, 2023 | Novo Nordisk is concluding research on Wegovy’s impact on osteoarthritis | Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning, all. Damian here with a look at the future of treating Duchenne muscular dystrophy, the departure of a... |
| Oct 24, 2023 | Insulin is increasingly affordable in the U.S. What about the rest of the world? | In March, Eli Lilly, Novo Nordisk, and Sanofi — the world’s three largest insulin manufacturers — committed to reducing the U.S. list price of insulin, a drug that millions of people require to live. Following two decades of sharp increases... |
| Oct 20, 2023 | Weight-loss drugs for first-graders? Eli Lilly is testing Mounjaro shots on kids as young as 6 | Health Weight-loss drugs for first-graders? Eli Lilly is testing Mounjaro shots on kids as young as 6 Hilary Brueck 2023-10-20T20:37:15Z Share icon An curved arrow pointing right. Share Facebook Icon The letter F. Facebook Email icon An env... |
| Oct 4, 2023 | The major biotech news updates you need to read today | Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning, everyone. Damian here with the precarious case of gene therapy in Europe, a long-awaited coup for Nova... |
| Sep 20, 2023 | Lilly sues compounders, wellness centers and spas over unapproved versions of Mounjaro | As the gold rush over weight-loss drugs accelerates, Eli Lilly filed lawsuits against several compounding pharmacies, spas and wellness centers around the U.S. for selling unapproved versions of its Mounjaro diabetes drug, which is frequent... |
| Jul 31, 2023 | The potential downsides of new blockbuster obesity drugs | Even as encouraging data fuels hype around a new class of obesity drugs, regulators and experts are racing to better understand possible health risks that are still emerging in a market projected to be worth tens of billions of dollars. Why... |
| Jun 27, 2023 | Lilly results add to buzz around weight loss drugs | Eli Lilly on Monday said its experimental weight loss drug retatrutide helped people lose as much as 24% of their weight over 48 weeks — the biggest reduction reported to date in clinical trials of obesity treatments. Why it matters: The re... |
| Jun 22, 2023 | Eli Lilly acquires biotech firm Dice Therapeutics for $2.4 billion | The pharmaceutical industry encompasses more than just weight-loss drugs. Eli Lilly, a prominent drug-making company, announced on Tuesday that it has agreed to acquire Dice Therapeutics, a specialized firm that focuses on developing oral t... |
| Jun 16, 2023 | The FDA needs a risk evaluation and mitigation strategy for Alzheimer’s drug lecanemab | Over the past several months, my conversations with colleagues in the Alzheimer’s field have featured an unusual sentiment: optimism inflected with worry. Optimism because, after years of failed studies and the disastrous accelerated approv... |
| Jun 15, 2023 | The CEO of pharma giant Eli Lilly shares 3 ways AI could transform his industry | David Ricks, the CEO of Eli Lilly. Eli Lilly Redeem now Sign up for notifications from Insider! Stay up to date with what you want to know. Subscribe to push notifications Read next Healthcare AI Artifical Intelligence More... Close icon Tw... |
| May 15, 2023 | Promising new Alzheimer's drugs face questions about real-world benefit | Promising clinical trial results from another new Alzheimer's drug haven't put to bed questions about how much the treatments actually benefit patients, and whether their strong points outweigh their safety risks. Why it matters: ... |
| May 3, 2023 | Eli Lilly says its experimental Alzheimer's drug appears to slow symptoms | Eli Lilly said Wednesday its experimental Alzheimer's drug appeared to slow worsening of the mind-robbing disease in a large study, sending its stock up by 5% on investor optimism about the results. In the 18-month trial, people in the... |
| May 3, 2023 | For Eli Lilly’s head scientist, Alzheimer’s results cap a 25-year scientific quest | If you flip to the 1,031st page of the May 1998 edition of the Journal of Cell Biology, you’ll find the first scientific byline for Daniel Skovronsky, then a young trainee at the University of Pennsylvania, on an article describing how beta... |
| May 3, 2023 | An experimental drug just showed it can help slow Alzheimer's, offering new hope for patients and a major boost to pharma giant Eli Lilly | A brain scan. BSIP/Universal Images Group via Getty Images Redeem now An experimental drug for Alzheimer's disease has cleared a big hurdle, moving it closer to approval. The pharma giant Eli Lilly said donanemab slowed cognitive decli... |
| Apr 28, 2023 | The difference between game-changer weight loss drugs semaglutide, tirzepatide, and liraglutide | Health The difference between game-changer weight loss drugs semaglutide, tirzepatide, and liraglutide Amber Middleton 2023-04-28T10:26:56Z Share icon An curved arrow pointing right. Share Facebook Icon The letter F. Facebook Email icon An ... |
| Apr 27, 2023 | The next game-changing weight loss drug just moved closer to FDA approval | Health The next game-changing weight loss drug just moved closer to FDA approval Gabby Landsverk 2023-04-27T16:07:34Z Share icon An curved arrow pointing right. Share Facebook Icon The letter F. Facebook Email icon An envelope. It indicates... |
| Mar 15, 2023 | In the News: Central Florida Nonprofit Welcomes Insulin Price Decreases | There’s no choice — I have to take insulin or I wouldn’t be sitting here,” — Elizabeth ForrestORLANDO, FLORIDA, USA, March 15, 2023 /EINPresswire.com/ -- Touched by Type 1, a widely recognized local non-profit focused on finding a cure for ... |
| Mar 11, 2023 | Medicare Doesn’t Pay For Obesity Drugs: Lifting This Coverage Prohibition Faces Considerable Hurdles | Medicare does not reimburse weight-loss medications. It's possible this restriction will be lifted ... [+] soon.getty |
| Mar 1, 2023 | Eli Lilly снизит цену на инсулин на 70% | Сегодня, 1 марта, американская фармацевтическая компания Eli Lilly объявила, что снижает цену на наиболее распространенные виды производимого ею инсулина на 70%. Так, самый дешевый инсулин компании будет продаваться по $25 против прежних $8... |
| Jan 21, 2023 | The promising new Alzheimer's drugs to watch — and the far-out ideas that could reshape how we treat the disease | A few companies are developing promising treatments for Alzheimer's disease. Miguel Medina/AFP/Getty Images 2023 is expected to be a big year for research on Alzheimer's treatments. One drug, called Leqembi, recently got a green l... |
| Jan 20, 2023 | The FDA Rejected Lilly’s Alzheimer’s Drug. Why It’s Only a Setback. | News that the Food and Drug Administration unexpectedly rejected Eli Lilly ‘s application for accelerated approval of a new Alzheimer’s treatment won’t be a major blow for the company. Eli Lilly said late Thursday that the FDA had turned do... |
| Dec 27, 2022 | 4 effective hair-loss treatments we discovered in 2022 | Health 4 effective hair-loss treatments we discovered in 2022 Hilary Brueck 2022-12-26T22:30:00Z Share icon An curved arrow pointing right. Share Facebook Icon The letter F. Facebook Email icon An envelope. It indicates the ability to send ... |
| Dec 22, 2022 | Pharmalittle: Merck pays Chinese biotech $175 million for cancer drugs; who will make a gene therapy for very sick kids? | Good morning everyone! Matthew Herper is here, filling in for Pharmalot, who is taking a well-deserved break, which means that today there’s English Breakfast tea instead of flavored coffee and two cozy cats instead of the usual mascot. Wha... |
| Dec 19, 2022 | Digital health news, funding round up in the prior week; December 19, 2022 | HistoSonics raised $100M; Memora Health and PeriGen partner; health spending reached $4.3T in 2021 Top Health News A Harris poll which asked respondents what data they would with a national database to prevent another public health emergenc... |
| Dec 17, 2022 | Nucor, CVS, and 11 More Companies That Raised Their Dividends This Week | Eli Lilly Amgen Nucor and Franklin Resources were among the many companies that declared dividend increases this week. Eli Lilly (ticker: LLY) declared a quarterly payout of $1.13 a share, an increase of 15% from 98 cents. The large pharmac... |
| Nov 20, 2022 | Acrivon Nets $100M for Protein Tech That Picks Patients for Targeted Cancer Meds | For targeted cancer therapy to work, it’s not enough to identify the right targets to hit with a drug. Just as important is selecting the patients appropriate for a given therapy. Scientists at Acrivon Therapeutics say their approach brings... |
| Nov 11, 2022 | Twitter verification trolls targeted the pharmaceutical firm Eli Lilly, falsely announcing that 'insulin is free' before claiming it would cost $400-per-vial | Two Twitter accounts pretended to be insulin-producing pharma firm Eli Lilly and Company. "Insulin is free now," one of the accounts tweeted, gaining 11,000 likes. Advertisement Two Twitter users bought verification to impersonate... |
| Nov 11, 2022 | Twitter verification trolls targeted the pharmaceutical firm Eli Lilly, falsely announcing that 'insulin is free' before claiming it would cost $400-per-vial | Twitter trolls used Elon Musk's paid verification feature to mock the pharmaceutical industry. Jakub Porzycki/NurPhoto via Getty Images; Gotham/FilmMagic Redeem now Two Twitter accounts pretended to be insulin-producing pharma firm Eli... |
| Nov 2, 2022 | The 10 Biggest Rounds Of October: LanzaTech Locks Up $500M, Form Energy Powers Up With $450M | 8 Shares Email Facebook Twitter LinkedIn This is a monthly feature that runs down the month’s top 10 funding rounds in the U.S. Check out last month’s edition here. September saw a couple of $1 billion rounds lead the way. However, the roun... |
| Oct 24, 2022 | Digital health news, funding round up in the prior week; October 24, 2022 | Eli Lilly acquired Akouos; Tempus raised $275M; Calm launched Calm Health Top Health News Pfizer asked the Supreme Court to decide whether a proposed program to help Medicare patients pay out-of-pocket costs for its tafamidis drugs—Vyndaqel... |
| Oct 18, 2022 | Tissue-agnostic drug development: FDA oncology center offers draft guidance | With the rise of Merck’s Keytruda and Bayer’s Vitrakvi, which have won accelerated approvals over the last five years for genetically-targeted (rather than tissue-targeted) cancer therapies, the FDA on Monday release... |
| Oct 17, 2022 | Meet the 16 pioneering biotech VCs who are taking new approaches to investing and reshaping the industry's future | Canaan; SciFounders; a16z; Global Health Investment; Istock; Vicky Leta/Insider This story is available exclusively to Insider subscribers. Become an Insider and start reading now. Insider found 16 pioneers in the world of biotech venture c... |
| Oct 11, 2022 | New generation of weight loss medications offer promise — but at a price | Excitement is building about a new generation of drugs that tout the ability to help adults with excess weight shed more pounds than older drugs on the market. Some patients, obesity medicine specialists say, are experiencing decreases in b... |
| Oct 6, 2022 | Lilly Gets Fast Track Designation for Obesity Drug | Eli Lilly moved one step closer for an approval to market its obesity treatment tirzepatide in the U.S. The drug could be a megablockbuster, and investors enthused over its potential have made the company’s stock the best-performing among i... |
| Jul 7, 2022 | Africa strikes deal with Pfizer for Covid-19 antiviral — report | Like a lot of Big Pharma outfits, Eli Lilly has some interesting projects going on for Covid-19. They have an early-stage antibody program in play with a partner, taken Olumiant and started work to see if it could help coronavirus patients.... |
| Jun 6, 2022 | A highly anticipated weight-loss drug helped people lose over 20% of their weight in a late-stage clinical trial, study finds | Health A highly anticipated weight-loss drug helped people lose over 20% of their weight in a late-stage clinical trial, study finds Rachel Hosie 2022-06-06T10:03:51Z Share icon An curved arrow pointing right. Share Facebook Icon The letter... |
| May 20, 2022 | Eli Lilly Gets Positive Opinion for Olumiant in Europe. The Stock Rises. | Eli Lilly and Incyte said Friday the European Medicines Agency’s Committee for Medicinal Products for Human Use issued a positive opinion for Olumiant for the treatment of adults with severe alopecia areata. Lilly (ticker: LLY) said in a pr... |
| Feb 3, 2022 | Pfizer sues two former employees for stealing trade secrets and creating a rival for diabetes and obesity drugs | Pfizer (PFE) has accused two former employees of clandestinely creating a pair of companies that are now using stolen trade secrets to develop obesity and diabetes medicines, which recently prompted Eli Lilly (LLY) to strike a collaboration... |
| Dec 10, 2021 | After investing in their Series B, Lilly bags a license for a batch of metabolic candidates | Eli Lilly will license in Regor Therapeutics therapies for metabolic disorders, as a part of an agreement announced Friday that will give the Chinese biotech an upfront payment of up to $50 million, part of which is an eq... |
| Dec 9, 2021 | Viatris and Biocon mull pooling their biosimilars into a $10B standalone company — report | As Eli Lilly works to consolidate its internal and Loxo teams into an oncology powerhouse, the drug giant is putting high hopes on CDK 4/6 inhibitor Verzenio to help drive the portfolio into the future. Now, the drug has scored a paradigm-a... |
| Nov 19, 2021 | Connect Biopharma celebrates a mid-stage win for its Dupixent rival, but shares tank after investors clamor for data | A suite of drugmakers is looking to topple Dupixent in the eczema market — and on Thursday, China-based Connect Biopharma uncorked some mid-stage results it says will pave the way to a pivotal trial. But investors want hard ... |
| Nov 3, 2021 | Molnupiravir: another Covid-19 treatment, another opportunity to recognize inequity | The Covid-19 pandemic has disproportionately affected communities of color and those with lower socioeconomic means, two groups that overlap to a significant extent in the U.S. Merck’s submission of molnupiravir, its oral antiviral drug, to... |
| Oct 26, 2021 | Q3 2021 Lilly Press Release | October 26, 2021 Eli Lilly and Company Lilly Corporate Center Indianapolis, Indiana 46285 U.S.A. +1.317.276.2000 www.lilly.com For Release: Final Refer to: Molly McCully; [email protected]; (317) 478-5423 (Media) Jordan Bishop; bishop... |
| Oct 7, 2021 | A federal drug purchasing program could save billions | When Amazon, Berkshire Hathaway, and JPMorgan announced they were creating a new health care company in 2018, it raised the possibility of the purchasing power such a company could have. Although the venture has since been disbanded, imagin... |
| Sep 8, 2021 | Eli Lilly bets on an RNA base editing outfit leveraging the body's own enzymes to reverse mutations | With its controversial Alzheimer’s med donanemab nearly ready for FDA scrutiny, Eli Lilly has grown more emboldened in its efforts to become the top dog in neuroscience. A new partnership with a quiet RNA editing player fo... |
Show more
Reviews 0
FAQ about investor.lilly.com
What has the press written about investor.lilly.com?
Parsers VC has collected 325 articles mentioning investor.lilly.com, among them “Eli Lilly hikes sales outlook, as CEO says there’s room for ‘dramatic’ obesity market expansion” (Oct 29, 2026) and “Lilly Stock Rises on Alzheimer Deal: Retatrutide Moat Still Not Fully Priced” (Aug 19, 2026).
Is investor.lilly.com still active?
investor.lilly.com is probably closed: its latest activity on Parsers VC dates from Nov 5, 2026.